Tag: Boehringer Ingelheim

Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales. Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for.

BI, Eli Lilly, Sanofi, Servier Develop Drug-Drug Interaction Risk Calculator

Elsevier, an information analytics business, is working together with a set of evaluation partners including Boehringer Ingelheim, Eli Lilly, Pierre Fabre, Sanofi, Servier, and others to develop a new...

FDA Approved Boehringer Ingelheim’s Ofev

boehringer
The U.S. Food and Drug Administration approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis ...

BI Announce $700m Deal for Lupin’s MEK Inhibitor Compound

Boehringer Ingelheim has signed a licensing, development and commercialisation deal worth more than $700m with Indian pharma company Lupin for the latter’s MEK inhibitor compound LNP3794. The p...

BI & MD Anderson Form Research and Development Center

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center(link is external) announced a new multi-year partnership to conduct collaborative research to rapidly advance therapies for v...

Boehringer Ingelheim Updated Real-World Data on Gilotrif

Boehringer Ingelheim announced updated, interim analysis results from the GioTag study, showing that initiating treatment with afatinib followed by osimertinib provided an overall survival (OS) of alm...

Boehringer Ingelheim Published Half-Year Results

boehringer ingelheim
In the first half of 2019, the research-driven pharmaceutical company Boehringer Ingelheim achieved further progress in research and development. In developing medicines, new approaches, and therapies...

FDA’s Arthritis Advisory Committee Recommended to Approve BI’s Ofev®

boehringer
Boehringer Ingelheim announced that the FDA’s Arthritis Advisory Committee recommended (10-7 vote) tor approve Ofev® (nintedanib) for the treatment of systemic sclerosis associated interstitial lung d...

BI and Bridge Biotherapeutics in New Collaboration and License Agreement

Boehringer Ingelheim and Bridge Biotherapeutics Inc. today announced that they are entering into a new collaboration and license agreement with the goal of developing Bridge Biotherapeutics’s autotaxi...

Boehringer Ingelheim Announced Acquisition of AMAL Therapeutics

boehringer
Boehringer Ingelheim announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic can...

BI Researchers Decode Speech to Help Detect Warning Signals for Schizophrenia or Alzheimer

boehringer
Can an app for speech recognition calculate a person’s individual risk of schizophrenia or Alzheimer’s Dementia? An international team of neuroscientists and IT specialists at Boehringer Ingelheim wan...

BI’s FRONTLINE® Brand Named Global ‘Brand of the Year’ 2019-2020

Boehringer Ingelheim, a global leader in animal health, is proud to announce that its FRONTLINE® brand was named global ‘Brand of the Year’ 2019-2020 in the Animalis Edition of the World Branding Awar...

BI, Yuhan to Develop Dual Agonist for the Treatment of Liver Diseases

Boehringer Ingelheim and Yuhan Corporation announced a collaboration and license agreement for the development of a first-in-class dual agonist for the treatment of NASH and related liver diseases tha...

Fast Track for BI and Lilly Chronic Heart Failure Drug

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to empagliflozin for the reduction of the risk of cardiovascular death and hospitalization for heart failure in people wi...

BI and University of Dundee Extend Anti-Cancer Alliance

cancer treatment
Following the success of their ongoing alliance, Boehringer Ingelheim and the University of Dundee extend their collaboration to develop new medicines that target and destroy key cancer causing protei...

BI and Eli Lilly Announced Detailed Findings from the CAROLINA® Trials

Boehringer Ingelheim and Eli Lilly and Company announced detailed findings from the CAROLINA® trial demonstrating that Tradjenta® (linagliptin) did not increase cardiovascular risk compared with glime...

FDA Accepted Boehringer, Lilly NDA for Triple Combination Tablet for Adults with Type 2 Diabetes

diabetes drugs
The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the investigational fixed-dose combination tablet of empagliflozin, linagliptin and metformin extended relea...